OBJECTIVES: Overcoming racial differences in acute coronary syndrome (ACS) outcomes is a strategic goal for U.S. health care. Genetic polymorphisms in the adrenergic pathway seem to explain some outcome differences by race in other cardiovascular diseases treated with β-adrenergic receptor blockade (BB). Whether these genetic variants are associated with survival among ACS patients treated with BB, and if this differs by race, is unknown. BACKGROUND: β-adrenergic receptor blockade after ACS is a measure of quality care, but the effectiveness across racial groups is less clear. METHODS: A prospective cohort of 2,673 ACS patients (2,072 Caucasian; 601 African-American) discharged on BB from 22 U.S. hospitals were followed for 2 years. Subjects were genotyped for polymorphisms in ADRB1, ADRB2, ADRA2C, and GRK5. We used proportional hazards regression to model the effect of genotype on mortality, stratified by race and adjusted for baseline factors. RESULTS: The overall 2-year mortality rate was 7.5% for Caucasians and 16.7% for African Americans. The prognosis associated with different genotypes in these BB-treated patients differed by race. In Caucasians, ADRA2C 322-325 deletion carriers had significantly lower mortality as compared with homozygous individuals lacking the deletion (hazard ratio: 0.46; confidence interval [CI]: 0.21 to 0.99; p = 0.047; race × genotype interaction p = 0.053). In African Americans, the ADRB2 16R allele was associated with significantly increased mortality (hazard ratio for RG vs. GG: 2.10; CI: 1.14 to 3.86; RR vs. GG: 2.65; CI: 1.38 to 5.08; p = 0.013; race × genotype interaction p = 0.096). CONCLUSIONS: Adrenergic pathway polymorphisms are associated with mortality in ACS patients receiving BB in a race-specific manner. Understanding the mechanism by which different genes impact post-ACS mortality differently in Caucasians and African Americans might illuminate opportunities to improve BB therapy in these groups.
OBJECTIVES: Overcoming racial differences in acute coronary syndrome (ACS) outcomes is a strategic goal for U.S. health care. Genetic polymorphisms in the adrenergic pathway seem to explain some outcome differences by race in other cardiovascular diseases treated with β-adrenergic receptor blockade (BB). Whether these genetic variants are associated with survival among ACS patients treated with BB, and if this differs by race, is unknown. BACKGROUND: β-adrenergic receptor blockade after ACS is a measure of quality care, but the effectiveness across racial groups is less clear. METHODS: A prospective cohort of 2,673 ACS patients (2,072 Caucasian; 601 African-American) discharged on BB from 22 U.S. hospitals were followed for 2 years. Subjects were genotyped for polymorphisms in ADRB1, ADRB2, ADRA2C, and GRK5. We used proportional hazards regression to model the effect of genotype on mortality, stratified by race and adjusted for baseline factors. RESULTS: The overall 2-year mortality rate was 7.5% for Caucasians and 16.7% for African Americans. The prognosis associated with different genotypes in these BB-treated patients differed by race. In Caucasians, ADRA2C 322-325 deletion carriers had significantly lower mortality as compared with homozygous individuals lacking the deletion (hazard ratio: 0.46; confidence interval [CI]: 0.21 to 0.99; p = 0.047; race × genotype interaction p = 0.053). In African Americans, the ADRB2 16R allele was associated with significantly increased mortality (hazard ratio for RG vs. GG: 2.10; CI: 1.14 to 3.86; RR vs. GG: 2.65; CI: 1.38 to 5.08; p = 0.013; race × genotype interaction p = 0.096). CONCLUSIONS: Adrenergic pathway polymorphisms are associated with mortality in ACS patients receiving BB in a race-specific manner. Understanding the mechanism by which different genes impact post-ACS mortality differently in Caucasians and African Americans might illuminate opportunities to improve BB therapy in these groups.
Authors: C P Cannon; A Battler; R G Brindis; J L Cox; S G Ellis; N R Every; J T Flaherty; R A Harrington; H M Krumholz; M L Simoons; F J Van De Werf; W S Weintraub; K R Mitchell; S L Morrisson; R G Brindis; H V Anderson; D S Cannom; W R Chitwood; J E Cigarroa; R L Collins-Nakai; S G Ellis; R J Gibbons; F L Grover; P A Heidenreich; B K Khandheria; S B Knoebel; H L Krumholz; D J Malenka; D B Mark; C R Mckay; E R Passamani; M J Radford; R N Riner; J B Schwartz; R E Shaw; R J Shemin; D B Van Fossen; E D Verrier; M W Watkins; D R Phoubandith; T Furnelli Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: David E Lanfear; Philip G Jones; Sharon Marsh; Sharon Cresci; Howard L McLeod; John A Spertus Journal: JAMA Date: 2005-09-28 Impact factor: 56.272
Authors: John A Spertus; Eric Peterson; John S Rumsfeld; Philip G Jones; Carole Decker; Harlan Krumholz Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: Maximilian T Lobmeyer; Yan Gong; Steven G Terra; Amber L Beitelshees; Taimour Y Langaee; Daniel F Pauly; Richard S Schofield; Karen K Hamilton; J Herbert Patterson; Kirkwood F Adams; James A Hill; Juan M Aranda; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2007-04 Impact factor: 2.089
Authors: M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman Journal: N Engl J Med Date: 1996-05-23 Impact factor: 91.245
Authors: Sharon Cresci; Jeremiah P Depta; Petra A Lenzini; Allie Y Li; David E Lanfear; Michael A Province; John A Spertus; Richard G Bach Journal: Circ Cardiovasc Genet Date: 2014-04-24
Authors: Ulrich H Frey; Jochen D Muehlschlegel; Jürgen Peters; Simon Body; Christoph Ochterbeck; Amanda A Fox; Stanton K Shernan; Charles D Collard; Peter Lichtner Journal: Anesthesiology Date: 2014-05 Impact factor: 7.892
Authors: Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas Journal: J Am Coll Cardiol Date: 2013-01-22 Impact factor: 24.094
Authors: Edward D Coverstone; Richard G Bach; LiShiun Chen; Laura J Bierut; Allie Y Li; Petra A Lenzini; Heidi C O'Neill; John A Spertus; Carmen C Sucharov; Jerry A Stitzel; Joel D Schilling; Sharon Cresci Journal: Basic Res Cardiol Date: 2018-08-10 Impact factor: 17.165
Authors: Jeffrey J Goldberger; Robert O Bonow; Michael Cuffe; Lei Liu; Yves Rosenberg; Prediman K Shah; Sidney C Smith; Haris Subačius Journal: J Am Coll Cardiol Date: 2015-09-29 Impact factor: 24.094
Authors: Li-Shiun Chen; Richard G Bach; Petra A Lenzini; John A Spertus; Laura Jean Bierut; Sharon Cresci Journal: Nicotine Tob Res Date: 2014-04-11 Impact factor: 4.244